1. Region II Infertility Prevention Project Advisory Committee May 16-17, 2007 New York, New York
Steven J. Shapiro
Infertility Prevention Project Coordinator
CDC/NCHHSTP/DSTDP/PTB (proposed)
Disclaimer: The findings and conclusions in this presentation are those of the author and do not necessarily represent the views of the Centers for Disease Control and Prevention.

2. Performance Measures Data Review
Region II and National Summary Data
Data Verification
Prevalence Monitoring and Performance Measure Data
Regional Summary
Project Area Snapshot

4. Performance Measure IPP CS1
Among clients of IPP Family Planning clinics, the proportion of women with positive chlamydia tests treated within 14 and 30 days of the date of specimen collection.

5. IPP CS 1 (Chlamydia) Results
Site
2004.1
2005.1
2005.2
2006.1
Region II- 14 Days (Average)
0.52
0.40
0.55
Region II- 30 Days (Average)
0.74
0.64
0.72
National- 14 Days (Average)
0.7
0.75
0.63
National- 30 Days (Average)
0.9
0.89
0.78
0.77

7. Performance Measure IPP CS2
Among clients of IPP Family Planning clinics, the proportion of women with positive gonorhea tests treated within 14 and 30 days of the date of specimen collection.

8. IPP CS 2 (Gonorrhea) Results
Site
2004.1
2005.1
2005.2
2006.1
Region II- 14 Days (Average)
0.55
0.51
0.53
Region II- 30 Days (Average)
0.74
0.61
0.67
0.72
National- 14 Days (Average)
0.7
0.64
0.65
National- 30 Days (Average)
0.9
0.91
0.75
0.77

10. Performance Measure CSPS MLS1
Proportion of female admittees to large juvenile detention centers tested for chlamydia.

11. CSPS MLS1 (JDC Screening) Results
Site
2004.1
2005.1
2005.2
2006.1
Region II (Average)
0.69
0.87
0.54
0.48
National (Average)
0.63
0.60
0.50
0.59

13. Data Verification Performance Measures Guidance:
IPP Family Planning Clinics: All family planning clinics that report data as part of the Chlamydia Prevalence Monitoring Project, regardless of whether they are integrated clinics or not.
Denominator: Total number of women who tested positive for chlamydia (at those family planning clinics)
In other words: If ten FP clinics in a jurisdiction report 500 CT positives and 9500 CT negatives to the prevalence monitoring database, then the denominator for the performance measure should be 500.

14. Prevalence Monitoring v
Prevalence Monitoring v. Performance Measure Females in IPP Family Planning Clinics Chlamydia and Gonorrhea 2005 Region II Summary
Region II
Prevalence Monitoring Positives
Performance Measure Denominator
Difference
Chlamydia
7423 (4/5)
9469
2046 (28%)
Gonorrhea
721 (3/5)
1121
400 (55%)

15. Reasons for Differences
2005 data
If Prev. Monitoring > Perf. Measures
Prevalence Monitoring data includes only those clinics who reported more than a total of 25 tests during the year
Not counting integrated clinics
If Prev. Monitoring < Perf. Measures
Non-prevalence monitoring FP sites submitting data for performance measures
Counting non-FP sites
???

16. Prevalence Monitoring v
Prevalence Monitoring v. Performance Measure Females in IPP Family Planning Clinics Chlamydia 2005
Grantee
Prevalence Monitoring Positives
Performance Measure Denominator
Difference
New Jersey
3010
2761
249 (8%)
NYC
1352
1435
83 (6%)
NYS
2765
4830
2065 (75%)
Puerto Rico
296
443
147 (50%)
Virgin Islands
159 NR
n/a

17. Prevalence Monitoring v
Prevalence Monitoring v. Performance Measure Females in IPP Family Planning Clinics Gonorrhea 2005
Grantee
Prevalence Monitoring Positives
Performance Measure Denominator
Difference
New Jersey
343
317
26 (8%)
NYC 70
298
228 (326%)
NYS
308
506
198 (64%)
Puerto Rico 14 NR
n/a
Virgin Islands 17

18. Questions?